Bard Financial Services Inc. Has $733,000 Position in Sanofi (NASDAQ:SNY)

Bard Financial Services Inc. lessened its holdings in shares of Sanofi (NASDAQ:SNY) by 15.6% in the fourth quarter, Holdings Channel.com reports. The fund owned 15,200 shares of the company’s stock after selling 2,800 shares during the quarter. Bard Financial Services Inc.’s holdings in Sanofi were worth $733,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Northwest Investment Counselors LLC bought a new stake in shares of Sanofi in the 3rd quarter valued at $29,000. Concord Wealth Partners increased its holdings in shares of Sanofi by 157.8% in the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after acquiring an additional 363 shares in the last quarter. Sunbelt Securities Inc. raised its position in shares of Sanofi by 72.1% during the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after purchasing an additional 313 shares during the period. Fortitude Family Office LLC raised its holdings in Sanofi by 708.6% during the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after buying an additional 659 shares during the period. Finally, Ashton Thomas Private Wealth LLC bought a new position in Sanofi in the second quarter valued at approximately $51,000. Institutional investors own 14.04% of the company’s stock.

Sanofi Stock Up 2.9 %

Shares of NASDAQ SNY traded up $1.41 during midday trading on Monday, reaching $49.56. The company’s stock had a trading volume of 1,605,248 shares, compared to its average volume of 1,426,169. The stock has a 50 day simple moving average of $49.13 and a 200-day simple moving average of $52.07. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $125.78 billion, a price-to-earnings ratio of 25.29, a PEG ratio of 1.23 and a beta of 0.57. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping the consensus estimate of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The firm had revenue of $13.44 billion for the quarter, compared to analysts’ expectations of $16.59 billion. During the same period in the previous year, the firm posted $2.55 EPS. The company’s revenue for the quarter was up 12.3% on a year-over-year basis. Equities research analysts predict that Sanofi will post 4.06 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on SNY. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.